[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cytomegaloviral-infection":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Cytomegaloviral Infection",19,17,[8,16,23,30,36,43,49,55,61,67,74,80,86,92,98,104,110,116,123],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07383649","Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection",[12],"Phase 2","RECRUITING","2026-08-26T02:15:28.524219Z","2026-05-05T02:43:28.731148Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07224763","Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD",[20],"Phase 1\u002FPhase 2","2026-08-26T02:14:59.425132Z","2026-05-05T02:43:28.114641Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05338658","Study of PAT in Patients With Solid Tumor Cancers",[27],"Phase 1","2026-08-26T02:17:22.153941Z","2026-05-05T02:43:27.915457Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT04706923","A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection",[12],"2026-08-03T03:23:28.660374Z","2026-05-05T02:43:27.843415Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT05319353","A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)",[40],"Phase 3","2026-08-26T02:15:22.311223Z","2026-05-05T02:43:27.612294Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT05801913","Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma",[27],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:27.275760Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06878560","Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD",[20],"2026-08-26T02:16:50.548894Z","2026-05-05T02:35:31.909367Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT07199465","A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)",[27],"2026-08-26T02:19:09.651016Z","2026-05-05T02:35:31.623428Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06407232","Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients",[40],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:28.359980Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":72,"content_modified":73},"NCT03665675","Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT",[71],"Early Phase 1","2026-08-26T02:18:51.009190Z","2026-05-05T02:43:26.962006Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":78,"content_modified":79},"NCT05432635","Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma",[27],"2026-08-26T02:16:07.529922Z","2026-04-29T02:57:57.084734Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":84,"content_modified":85},"NCT06059391","CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant",[12],"2026-08-26T02:16:01.910993Z","2026-05-05T02:35:31.868600Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT06798909","Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients",[40],"2026-08-26T02:18:18.766496Z","2026-05-05T02:43:27.509378Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT05708755","CMV Immunity Monitoring in Lung Transplant Recipients",[12],"2026-08-26T02:19:25.538428Z","2026-05-05T02:43:26.771159Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT07020533","A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant",[27],"2026-08-26T02:18:31.944757Z","2026-05-05T02:43:28.960514Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT02982902","T Cell Therapy of Opportunistic Cytomegalovirus Infection",[71],"2026-08-26T02:16:24.135291Z","2026-05-05T02:43:29.669092Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT04230356","Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant",[12],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:28.418059Z",{"nct_id":117,"title":118,"phases":119,"status":120,"updated_at":121,"content_modified":122},"NCT07513623","Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II",[12],"NOT_YET_RECRUITING","2026-08-26T02:17:57.997171Z","2026-05-05T02:43:29.587452Z",{"nct_id":124,"title":125,"phases":126,"status":120,"updated_at":128,"content_modified":129},"NCT07706166","Letermovir for R+ Study",[127],"Phase 4","2026-08-26T02:17:28.381459Z","2026-07-19T19:36:05.087065Z"]